Search

for
Search:

GlossaryVismodegib

medication treats skin cancer by inhibiting Hedgehog signaling pathway

Vismodegib is a medication used to treat basal cell carcinoma, a type of skin cancer. It works by inhibiting the Hedgehog signaling pathway, which is involved in the growth and spread of cancer cells. This drug is particularly useful for patients with advanced stages of the disease or those who cannot undergo surgery or radiation.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 93 results

research Alopecia in Patients Treated with Molecularly Targeted Anticancer Therapies

44 citations , September 2015 in “Annals of Oncology”

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

research Adverse Hair Reactions to New Targeted Therapies for Cancer

1 citations , March 2019 in “Actas Dermo-Sifiliográficas”

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

research Malignant Epithelial Tumors: Part II. Therapy and Prevention

5 citations , January 2013 in “Journal der Deutschen Dermatologischen Gesellschaft”

The document concludes that individualized treatment for malignant epithelial tumors is necessary and more research on metastatic squamous cell carcinoma treatments is needed.

research Roles of the Hedgehog Signaling Pathway in Cutaneous Physiology and Oncology

June 2019 in “International journal of dermatology and venereology”

The Hedgehog Signaling Pathway is important for skin and hair development and skin cancer treatment, but more research is needed to understand it fully.

Smoothened Receptor Inhibitor Vismodegib for the Treatment of Basal Cell Carcinoma: A Retrospective Analysis of Efficacy and Side Effects

research Smoothened Receptor Inhibitor Vismodegib for the Treatment of Basal Cell Carcinoma: A Retrospective Analysis of Efficacy and Side Effects

8 citations , May 2019 in “Journal of dermatological treatment”

Vismodegib is effective for basal cell carcinoma but has severe side effects.

View more "vismodegib" in research →

Community Join

0 / 0 results

— no results